Associations between decreased BMP6 expression and tumorigenesis, high malignant potential, and/or poorer survival were reported in patients with breast cancer, gastric cancer, and NSCLC (33–39), whereas opposite associations were reported in prostate cancer (40–42). This evidence concerns the gene BMP6 and prostate carcinoma.